Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antigens, Neoplasm | 5 | 2019 | 132 | 1.330 |
Why?
|
| Software | 5 | 2019 | 418 | 1.290 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 35 | 0.870 |
Why?
|
| CTLA-4 Antigen | 2 | 2019 | 45 | 0.730 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 116 | 0.720 |
Why?
|
| Computer Graphics | 2 | 2018 | 37 | 0.690 |
Why?
|
| Mutation | 5 | 2018 | 1213 | 0.650 |
Why?
|
| Microscopy, Fluorescence | 1 | 2019 | 261 | 0.640 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2018 | 24 | 0.630 |
Why?
|
| Forecasting | 1 | 2018 | 277 | 0.570 |
Why?
|
| Epitopes | 1 | 2016 | 146 | 0.550 |
Why?
|
| Protein Binding | 2 | 2019 | 1027 | 0.540 |
Why?
|
| Genomics | 2 | 2018 | 168 | 0.530 |
Why?
|
| Ovarian Neoplasms | 1 | 2018 | 267 | 0.530 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 689 | 0.530 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 597 | 0.520 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 446 | 0.500 |
Why?
|
| Biomarkers | 1 | 2019 | 1593 | 0.460 |
Why?
|
| Melanoma | 1 | 2016 | 335 | 0.430 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 66 | 0.300 |
Why?
|
| Immunotherapy | 3 | 2019 | 215 | 0.300 |
Why?
|
| Cancer Vaccines | 2 | 2019 | 61 | 0.300 |
Why?
|
| Genome | 2 | 2018 | 54 | 0.280 |
Why?
|
| Neoplasms | 4 | 2019 | 1667 | 0.270 |
Why?
|
| Ipilimumab | 2 | 2019 | 10 | 0.200 |
Why?
|
| Clone Cells | 1 | 2021 | 67 | 0.200 |
Why?
|
| Microfluidics | 1 | 2021 | 22 | 0.190 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2019 | 300 | 0.190 |
Why?
|
| Tumor Microenvironment | 2 | 2019 | 213 | 0.190 |
Why?
|
| Humans | 15 | 2021 | 68618 | 0.180 |
Why?
|
| Epitope Mapping | 1 | 2019 | 10 | 0.170 |
Why?
|
| Cell Size | 1 | 2019 | 76 | 0.170 |
Why?
|
| Interleukin-15 Receptor alpha Subunit | 1 | 2019 | 10 | 0.170 |
Why?
|
| Antigen-Presenting Cells | 1 | 2019 | 50 | 0.170 |
Why?
|
| Signal Transduction | 2 | 2019 | 2689 | 0.170 |
Why?
|
| HLA Antigens | 1 | 2019 | 82 | 0.170 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2019 | 77 | 0.170 |
Why?
|
| Tumor Hypoxia | 1 | 2018 | 3 | 0.170 |
Why?
|
| Genetic Engineering | 1 | 2019 | 41 | 0.160 |
Why?
|
| Killer Cells, Natural | 1 | 2019 | 94 | 0.160 |
Why?
|
| Interleukin-15 | 1 | 2019 | 66 | 0.160 |
Why?
|
| Genes, MHC Class I | 1 | 2018 | 14 | 0.160 |
Why?
|
| Adoptive Transfer | 1 | 2019 | 100 | 0.160 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 284 | 0.160 |
Why?
|
| Neoplasms, Experimental | 1 | 2019 | 118 | 0.160 |
Why?
|
| Algorithms | 3 | 2019 | 1196 | 0.160 |
Why?
|
| Phenotype | 1 | 2021 | 947 | 0.160 |
Why?
|
| Platinum | 1 | 2018 | 17 | 0.150 |
Why?
|
| Caenorhabditis elegans | 1 | 2018 | 38 | 0.150 |
Why?
|
| Immunity, Innate | 1 | 2018 | 156 | 0.150 |
Why?
|
| Protein Kinases | 1 | 2018 | 122 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 226 | 0.150 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 68 | 0.150 |
Why?
|
| Urologic Neoplasms | 1 | 2017 | 14 | 0.150 |
Why?
|
| Ligands | 1 | 2018 | 317 | 0.140 |
Why?
|
| Neoplastic Stem Cells | 1 | 2018 | 84 | 0.140 |
Why?
|
| B7-H1 Antigen | 1 | 2017 | 30 | 0.140 |
Why?
|
| Chickens | 1 | 2018 | 232 | 0.140 |
Why?
|
| Internet | 2 | 2018 | 390 | 0.140 |
Why?
|
| Data Interpretation, Statistical | 1 | 2018 | 329 | 0.140 |
Why?
|
| Animals | 6 | 2019 | 20881 | 0.140 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2016 | 231 | 0.140 |
Why?
|
| Programming Languages | 1 | 2016 | 16 | 0.140 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2016 | 15 | 0.130 |
Why?
|
| Radiation Oncology | 1 | 2015 | 12 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 266 | 0.130 |
Why?
|
| Carcinoma | 1 | 2017 | 215 | 0.130 |
Why?
|
| Data Mining | 1 | 2015 | 45 | 0.130 |
Why?
|
| Radiosurgery | 1 | 2016 | 66 | 0.130 |
Why?
|
| Peptides | 1 | 2018 | 455 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2018 | 448 | 0.120 |
Why?
|
| Aged | 4 | 2018 | 14862 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 468 | 0.120 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 1083 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 511 | 0.120 |
Why?
|
| Machine Learning | 1 | 2016 | 170 | 0.120 |
Why?
|
| Macrophages | 1 | 2018 | 647 | 0.120 |
Why?
|
| Cells, Cultured | 1 | 2019 | 2673 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 756 | 0.110 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 4848 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 561 | 0.110 |
Why?
|
| Middle Aged | 4 | 2018 | 21147 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2015 | 310 | 0.100 |
Why?
|
| Prognosis | 1 | 2016 | 2093 | 0.100 |
Why?
|
| Female | 6 | 2019 | 38074 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 1070 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 1173 | 0.080 |
Why?
|
| Male | 6 | 2019 | 37321 | 0.070 |
Why?
|
| Adult | 3 | 2018 | 21403 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2016 | 7029 | 0.060 |
Why?
|
| Precision Medicine | 2 | 2015 | 111 | 0.060 |
Why?
|
| Mice | 3 | 2019 | 8474 | 0.050 |
Why?
|
| HLA-D Antigens | 1 | 2019 | 20 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 53 | 0.040 |
Why?
|
| Cell Degranulation | 1 | 2019 | 24 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2019 | 57 | 0.040 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2019 | 7 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 2019 | 76 | 0.040 |
Why?
|
| Fas Ligand Protein | 1 | 2019 | 64 | 0.040 |
Why?
|
| fas Receptor | 1 | 2019 | 54 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2018 | 66 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 91 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2018 | 63 | 0.040 |
Why?
|
| Alleles | 1 | 2019 | 386 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 304 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 65 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2018 | 48 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2019 | 199 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 397 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 2018 | 135 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 34 | 0.040 |
Why?
|
| Urothelium | 1 | 2017 | 22 | 0.040 |
Why?
|
| Exome | 1 | 2017 | 20 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 714 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2018 | 230 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2018 | 307 | 0.030 |
Why?
|
| Gene Expression | 1 | 2019 | 770 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 135 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 151 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 1033 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2015 | 86 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1054 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 706 | 0.030 |
Why?
|
| Data Collection | 1 | 2015 | 420 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 622 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1465 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2550 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 4655 | 0.020 |
Why?
|